Author(s)

M. A. Nezami¹, Steven Hager², Jessica Garner¹

¹Pacific Medical Center of Hope, Fresno, CA, USA.
²cCARE Cancer Treatment Center, Fresno, CA, USA.

In most cases, cancer develops as a result of non-inheritable somatic mutations (epimutations), acquired by the individual adult cell, during the evolution of the cell, and propagated into an expanding clone of progeny of the cells by natural selection [1]. The role of microenvironment in selection for such acquired mutations, or epimutations, is a focus of scientific research in carcinogenesis [2]. Here we describe a defective DNA response to hypoxia due to epigenetic aberrancies, in cancer cellular biology [3]. We also summarize a literature review on hypoxia mediated epigenetic responses, and its role in carcinogenesis and metastasis. Further, we review a novel method of treating hypoxic solid tumors with a combination of epigenetic modifiers with both in vitro and in vivo results in human, translating to an improved prognosis and clinical outcome. We propose that this approach both independently and synergistically (with the current standard of care) can provide an improved outcome.

Epigenetic, Hypoxia, Epimutations, Hypoxia Inducible Factor 1, Circulatory Tumor DNA, Circulatory Tumor Cells

Nezami, M. , Hager, S. and Garner, J. (2016) Epigenetic Tumor Response to Hypoxia: An Epimutation Pattern and a Method of Multi Targeted Epigenetic Therapy (MTET). Journal of Cancer Therapy, 7, 254-269. doi: 10.4236/jct.2016.74027.